Retatrutide: Triple-Receptor Agonist Research Guide

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that acts simultaneously on three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-agonist profile distinguishes it from earlier-generation compounds such as semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist).

In preclinical and clinical research, Retatrutide has demonstrated notable effects on metabolic regulation, appetite signalling, energy expenditure, and body composition. It is often referred to informally as a "triple G" agonist.

The tri-receptor mechanism of Retatrutide allows it to engage distinct but complementary metabolic pathways simultaneously:

• GLP-1 receptor activation — stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite via central and peripheral signalling
• GIP receptor activation — potentiates insulin response to glucose, modulates adipogenesis, and may synergise with GLP-1 signalling for enhanced metabolic effects
• Glucagon receptor activation — increases hepatic glucose output and energy expenditure, counterbalancing the appetite-suppressive effects with thermogenic activity

This convergence of mechanisms is the basis for research interest in Retatrutide's potential for studying metabolic syndrome, obesity, and related conditions.

A Phase 2 clinical trial (NEJM, 2023) evaluated Retatrutide across multiple dose levels in adults with obesity over 48 weeks. Key findings from the highest-dose cohort included mean body weight reductions exceeding 20%, with significant improvements in secondary metabolic markers including fasting glucose, triglycerides, and waist circumference.

The compound demonstrated a dose-dependent response profile. Phase 3 trials are ongoing as of 2026. Retatrutide remains a research compound — it is not approved for therapeutic use in Australia or globally.

RetaLABS Retatrutide is supplied as a lyophilised (freeze-dried) powder. Recommended reconstitution protocol for research use:

• Add bacteriostatic water slowly to the vial along the glass wall — do not inject directly onto the powder
• Gently swirl until fully dissolved — do not vortex or shake
• Typical research concentration: 2–5mg/mL depending on protocol
• Store lyophilised vials at −20°C, protected from light
• Reconstituted solution: refrigerate at 2–8°C, use within 4 weeks
• Avoid repeated freeze-thaw cycles

RetaLABS Retatrutide is manufactured to >99% purity, verified by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). Certificates of Analysis are available on request. All products are supplied for laboratory and research purposes only.